Louistram Injection contains Levetiracetam 100 mg as its active ingredient and is indicated for the treatment of epilepsy. Levetiracetam is an anticonvulsant agent used as adjunctive therapy in the management of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. The exact mechanism of action is not fully understood; however, it is believed to modulate synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability. Louistram Injection is administered intravenously, providing rapid onset of action, which is particularly beneficial in acute seizure management or when oral administration is not feasible. The dosage should be individualized based on the patient’s clinical condition, renal function, and response to therapy. Common adverse effects may include somnolence, dizziness, headache, and fatigue, while serious adverse reactions are rare but can include hypersensitivity and psychiatric symptoms such as agitation or depression. Caution is advised in patients with renal impairment, and regular monitoring is recommended. Louistram Injection should be used under strict medical supervision, ensuring appropriate seizure control while minimizing potential side effects.